Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- COVID-19 (1)
- Card-based payment (1)
- Chip (1)
- Commerce Clause (1)
- Contactless (1)
-
- Coronavirus (1)
- Cross-border trade (1)
- Essential goods (1)
- Health crisis (1)
- Institutional payment (1)
- Law (1)
- Lock down (1)
- No contact (1)
- Novel corona virus (1)
- Pandemic (1)
- Phone-based payment (1)
- Prescription pharmaceuticals (1)
- Public health (1)
- Public threat (1)
- Quarantine (1)
- Retail transaction (1)
- Sustainable society (1)
- Swipe (1)
Articles 1 - 2 of 2
Full-Text Articles in Commercial Law
Driver For Contactless Payments, Ronald J. Mann
Driver For Contactless Payments, Ronald J. Mann
Faculty Scholarship
As a consumer, my primary experience with cash before the virus was standing in checkout lines observing the sluggish pace of cash transactions in front of me. Like so many things in our lives, the advent of the virus has changed the situation markedly. From the earliest days of infection, it has been far more unsettling to observe cash transactions knowing that the virus persists on paper and metal surfaces for days.
The dynamic that has driven the choices merchants offer in face-to-face retail transactions will change as well. Driven by the private exigencies of the retail environment, the last …
Oy Canada! Trade's Non-Solution To "The Problem" Of U.S. Drug Prices, Daniel Gilman
Oy Canada! Trade's Non-Solution To "The Problem" Of U.S. Drug Prices, Daniel Gilman
Faculty Scholarship
Price disparities—price “differentiation” or “discrimination”—in pharmaceuticals markets have, in recent years, been the subject of much discussion. Price sensitivity should come as no surprise: Medicines play an increasingly important role in healthcare, while pharmaceuticals prices continue to rise. When prices vary greatly within markets or between neighboring markets, the pressure towards arbitrage is clear. This paper considers the question whether the re-importation of medicines from Canada or the EU is well advised and argues that it is not. First, we might reasonably question the extent to which we wish, as a matter of policy, to manage pharmaceuticals pricing; among other …